Table 4.
Anti-SARS-CoV-2 vaccines in therapeutic use at the time of writing
| Sponsor | Name of vaccine | Antigen generation | No. of doses needed | Efficacy [ref for Phase III study] | Storage |
|---|---|---|---|---|---|
| Oxford University and AstraZeneca | AZD1222 | DNA in recombinant non-replicating adenoviral vector | 2 (4–12 weeks apart) | 62% (confirmed symptomatic COVID-19 infection) [37] | Normal refrigeration (2–8 °C) |
| Gamaleya | Sputnik V | DNA in recombinant non-replicating adenoviral vector | 2 (3 weeks apart) | 92% (confirmed symptomatic COVID-19) [38] | Normal refrigeration (2–8 °C) |
| Moderna/NIH | mRNA-1273 | mRNA contained within liposomes | 2 (4 weeks apart) | 94% (confirmed symptomatic COVID-19) [39] | Between − 25 °C and − 15 °C (2–8 °C for up to 30 days thawed) |
| Pfizer/BioNTech | BNT162b2 | mRNA contained within liposomes | 2 (3 weeks apart) | 95% (confirmed symptomatic COVID-19) [40] | − 80 °C to − 60 °C and up to 120 h at 2–8 °C after thawing |
| Sinopharm | BBIBP-CorV | Inactivated SARS-CoV-2 virus | 2 (3 weeks apart) | 79% (precise endpoint unclear) [41]a | Normal refrigeration (2–8 °C) |
| Janssen (Johnson & Johnson) | Ad26.COV2.S or JNJ-78436725 | DNA in recombinant non-replicating adenoviral vector | 1 | 66% (confirmed moderate or severe COVID-19 [42]a | Normal refrigeration (2–8 °C) |
| Novavax | NVX-CoV2373 | Recombinant viral spike proteins | 2 (3 weeks apart) | 89% (confirmed symptomatic COVID-19) [43]a | Normal refrigeration (2–8 °C) |